invest1 publisher
Two Korean biotech IPOs raised 24.5 billion won less than the top of their ranges
Skylabs and Ingenia Therapeutics priced at or below the floor of their indicative ranges after institutions pledged 0.17% and 2.23% of bids to lockups. Both stocks have since traded above the top of those ranges.
Publishers:en.sedaily.com
Reality
- Evidence58
- Adoption46
- Hype gap+22
- Incentives52
- Confidence62